Literature DB >> 31165998

Soluble CLEC-2 is generated independently of ADAM10 and is increased in plasma in acute coronary syndrome: comparison with soluble GPVI.

Osamu Inoue1, Makoto Osada2,3, Junya Nakamura4, Fuminori Kazama2, Toshiaki Shirai2, Nagaharu Tsukiji2, Tomoyuki Sasaki2, Hiroshi Yokomichi5, Tomotaka Dohi6, Makoto Kaneko7, Makoto Kurano7, Mitsuru Oosawa4, Shogo Tamura2,8, Kaneo Satoh2, Katsuhiro Takano2, Katsumi Miyauchi6, Hiroyuki Daida6, Yutaka Yatomi7, Yukio Ozaki9, Katsue Suzuki-Inoue10.   

Abstract

Soluble forms of platelet membrane proteins are released upon platelet activation. We previously reported that soluble C-type lectin-like receptor 2 (sCLEC-2) is released as a shed fragment (Shed CLEC-2) or as a whole molecule associated with platelet microparticles (MP-CLEC-2). In contrast, soluble glycoprotein VI (sGPVI) is released as a shed fragment (Shed GPVI), but not as a microparticle-associated form (MP-GPVI). However, mechanism of sCLEC-2 generation or plasma sCLEC-2 has not been fully elucidated. Experiments using metalloproteinase inhibitors/stimulators revealed that ADAM10/17 induce GPVI shedding, but not CLEC-2 shedding, and that shed CLEC-2 was partially generated by MMP-2. Although MP-GPVI was not generated, it was generated in the presence of the ADAM10 inhibitor. Moreover, antibodies against the cytoplasmic or extracellular domain of GPVI revealed the presence of the GPVI cytoplasmic domain, but not the extracellular domain, in the microparticles. These findings suggest that most of the GPVI on microparticles are induced to shed by ADAM10; MP-GPVI is thus undetected. Plasma sCLEC-2 level was 1/32 of plasma sGPVI level in normal subjects, but both soluble proteins significantly increased in plasma of patients with acute coronary syndrome. Thus, sCLEC-2 and sGPVI are released by different mechanisms and released in vivo upon platelet activation.

Entities:  

Keywords:  ADAM10; Biomarker; Platelets; Soluble CLEC-2; Soluble GPVI

Mesh:

Substances:

Year:  2019        PMID: 31165998     DOI: 10.1007/s12185-019-02680-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  6 in total

Review 1.  Platelet Membrane Receptor Proteolysis: Implications for Platelet Function.

Authors:  Jiayu Wu; Johan W M Heemskerk; Constance C F M J Baaten
Journal:  Front Cardiovasc Med       Date:  2021-01-08

2.  Elevated Plasma Soluble C-Type Lectin-like Receptor 2 Is Associated with the Worsening of Coronavirus Disease 2019.

Authors:  Hideo Wada; Yuhuko Ichikawa; Minoru Ezaki; Akitaka Yamamoto; Masaki Tomida; Masamichi Yoshida; Shunsuke Fukui; Isao Moritani; Katsuya Shiraki; Motomu Shimaoka; Toshiaki Iba; Katsue Suzuki-Inoue; Hideto Shimpo
Journal:  J Clin Med       Date:  2022-02-14       Impact factor: 4.241

3.  Rac Inhibition Causes Impaired GPVI Signalling in Human Platelets through GPVI Shedding and Reduction in PLCγ2 Phosphorylation.

Authors:  Raluca A I Neagoe; Elizabeth E Gardiner; David Stegner; Bernhard Nieswandt; Steve P Watson; Natalie S Poulter
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

4.  Association between c-type lectin-like receptor 2 and microsatellite instability in colorectal cancer: a cross-sectional study.

Authors:  Xin Zhang; Jia-Rui Yuan; Xin Wang; Shuang Fu; Rui-Tao Wang; Guang-Yu Wang
Journal:  BMC Cancer       Date:  2022-07-28       Impact factor: 4.638

Review 5.  The Role of CLEC-2 and Its Ligands in Thromboinflammation.

Authors:  Danyang Meng; Man Luo; Beibei Liu
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

6.  Soluble C-Type Lectin-Like Receptor 2 Elevation in Patients with Acute Cerebral Infarction.

Authors:  Akisato Nishigaki; Yuhuko Ichikawa; Minoru Ezaki; Akitaka Yamamoto; Kenji Suzuki; Kei Tachibana; Toshitaka Kamon; Shotaro Horie; Jun Masuda; Katsutoshi Makino; Katsuya Shiraki; Hideto Shimpo; Motomu Shimaoka; Katsue Suzuki-Inoue; Hideo Wada
Journal:  J Clin Med       Date:  2021-07-30       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.